Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Dec 2, 2022

Provention Bio Announces the Grant of Inducement Awards
Dec 2, 2022

Sanofi to showcase new data from oncology portfolio spanning marketed products and investigational compounds at ASH 2022

Four Sarclisa® (isatuximab-irfc) oral presentations and 11 posters featuring cutting-edge investigational and marketed therapies to be presented
Nov 30, 2022

Sanofi to present new clinical data reinforcing novel therapies across rare blood disorders at ASH 2022
Nov 17, 2022

TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
Nov 4, 2022

Provention Bio Announces the Grant of Inducement Awards
Nov 3, 2022

Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 13, 2022

Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022
Oct 7, 2022

Provention Bio Announces the Grant of Inducement Awards
Oct 6, 2022

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Oct 6, 2022

Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.